Posted by Michael Wonder on 23 Oct 2019
FDA approves Fiasp for use in insulin infusion pumps for adults with type 1 or type 2 diabetes
22 October 2019 - Novo Nordisk today announced that the U.S. FDA has expanded the label for Fiasp (insulin aspart injection) 100 u/mL to include use in insulin infusion pumps for the improvement of glycemic control in adults with type 1 or type 2 diabetes.
Fiasp, a rapid-acting insulin, was approved by the FDA in 2017 for use by intravenous infusion under supervision by a healthcare professional or by subcutaneous multiple daily injection in adults with diabetes.
The label change is based on the FDA's review of data from the onset 5 clinical trial, which confirmed the efficacy and safety of Fiasp when used in insulin infusion pumps in adults with diabetes.
